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Control of blood flow distribution and tissue homeostasis depend on the tight regulation of and coordination
between the microvascular network and circulating blood cells. Channels formed by connexins or pannexins that
connect the intra- and extracellular compartments allow the release of paracrine signals, such as ATP and
prostaglandins, and thus play a central role in achieving fine regulation and coordination of vascular function. This
review focuses on vascular connexin hemichannels and pannexin channels. We review their expression pattern
within the arterial and venous system with a special emphasis on how post-translational modifications by
phosphorylation and S-nitrosylation of these channels modulate their function and contribute to vascular
homeostasis. Furthermore, we highlight the contribution of these channels in smooth muscle cells and
endothelial cells in the regulation of vasomotor tone as well as how these channels in endothelial cells
regulate inflammatory responses such as during ischemic and hypoxic conditions. In addition, this review will
touch on recent evidence implicating a role for these proteins in regulating red blood cell and platelet
function.
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The vascular system is a complex network that, according
to the structure and function of the vessels, can be divided
into two compartments: the arterial and venous circula-
tions, which are connected through the capillaries. Both
compartments can be subdivided into different vascular
segments. In the arterial circulation, conduit arteries,
resistance arteries and arterioles can be recognized,
and in the venous circulation, post-capillary venules,
venules and veins can be distinguished [1–3]. All these
vascular segments are designed to perform different, but* Correspondence: xfigueroa@bio.puc.cl
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and nutrients to all individual cells of the organism
and dispose of metabolic wastes, which can only be
achieved by fine regulation and coordination of vas-
cular function along the different segments. As blood
vessels are complex structures formed by several cell
types, control of vascular function depends on timely
and precise communication between the different cel-
lular components of the vessel wall, mainly smooth
muscle cells (SMCs) and endothelial cells (ECs) [4–6].
Nevertheless, blood vessels must also work in coordin-
ation with cells that are part of the blood, such as red
blood cells (RBCs) and platelets [7, 8]. Thus, the control
of vascular function depends on the fine communication
between diverse cell types that are not always in direct
contact each other.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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is mediated by the release of autocrine/paracrine signals.
Nitric oxide (NO), prostaglandins and ATP are widely
recognized autocrine/paracrine signals that play diverse
roles in the control of vascular function, such as regulation
of vasomotor tone, smooth muscle proliferation, platelet
aggregation, vascular permeability and leucocyte trans-
migration [9–12]. In addition, a signaling mechanism
known as endothelium-derived hyperpolarization (EDH)
has also been found to play an important role in the
control of vasomotor tone [4, 9–14]. Although the
biochemical identity of this signal is still controversial,
it has been consistently found that the initiation of
EDH signaling depends on the hyperpolarization of ECs
by the activation of Ca2+-activated K+ channels of small
(SKCa) and intermediate (IKCa) conductance, which, in the
vascular wall, are only expressed in the endothelium
[4, 9–13]. Additionally to autocrine/paracrine signaling,
the direct cell-to-cell communication via connexin-formed
gap junction channels make an important contribution to
the coordination of function between the different cell
types of the vessel wall and among distinct segments of the
vascular network in the microcirculation [15–17]. It is
interesting to note that ECs and SMCs are functionally
connected by gap junctions, which led to hypothesize that
the EDH signaling corresponds to direct transmission of
the hyperpolarizing current generated in ECs to SMCs
through a gap junction-mediated pathway [4, 13].
Remarkably, connexin (Cx) proteins do not form only
gap junction channels, but also may form functional
hemichannels (i.e. half of a gap junction channel) that
connect the cytoplasm with the extracellular milieu.
Communication of the intracellular compartment with
the extracellular space through low resistance membrane
channels formed by connexins (i.e. gap junctions) or the
structurally related proteins termed pannexins (Panxs) has
emerged as key pathways to command and regulate
several paracrine signaling mechanisms involved in the
control of vascular function [4, 18–21]. In this review, we
discuss the structure, regulation and function of gap
junctions, connexin hemichannels and pannexin channels
in the vasculature and briefly in the circulating anuclear
cells that regulate vascular function, red blood cells
(RBCs) and platelets.
Structure of Connexin and Pannexin Proteins
Connexin and pannexin proteins are thought to belong to
the same superfamily as they share some physic-chemical
properties, such as the charged nature of the extracellular
loop and the polar residue distribution in the transmem-
brane helices [22]. However, it remains to be determined
if they evolved from a common ancestor or if they evolved
convergently. All connexins and pannexins possess a
similar structure with 4 transmembrane domains, twoextracellular loops, an intracellular loop, and both the
amino and carboxyl termini located intracellularly [23].
Generally, either six connexins or six pannexins come
together and form a channel, except for Panx2 that seems
to form heptamers or octamers [24]. A connexin-based
hexamer is referred to as a connexin hemichannel [25].
Two connexin hemichannels from adjacent cells are able
to dock and form a gap junction channel. Pannexin
oligomers form pannexin channels in the membrane,
similar to connexin hemichannels; however, there is
limited evidence in vertebrates for pannexin channels to
dock with channels of neighboring cells to form functional
pannexin-formed gap junction channels [26].
In the human genome, there are 21 known isoforms of
connexins that were originally grouped into three
subfamilies, α, β, and γ; however, recent analyses of the
evolution of connexins have regrouped them into five
subfamilies, adding δ and ζ [22]. Cx32, Cx37, Cx40,
Cx43, Cx45 and Cx47 are expressed in the vascular
system, where Cx37, Cx40 and Cx43 are alpha connexins,
Cx45 and Cx47 are gamma connexins, and Cx32 is a beta
connexin [22]. All connexin isoforms have conserved
regions of the second transmembrane domain, within the
amino termini, and conserved cysteine residues in the
extracellular loops [22]. The cytoplasmic loop and
carboxyl terminus are the least conserved regions between
connexins allowing for differential regulation of each con-
nexin isoform and thus participation in unique signaling
cascades, especially when multiple isoforms are expressed
within the same cell [22]. Unlike connexins, there are only
three mammalian pannexin isoforms, Panx1, Panx2 and
Panx3, which share conserved regions in their extracellular
loops, intracellular loop, and amino and carboxyl termini
[20, 22, 26]. Panx1 and Panx2 each have two splice variants
while the connexins are suggested to have splicing variants
of their 5’-untranslated region, which can impact the
translation and function of the proteins [26, 27].
Connexin and pannexin expression in the vascular wall
Connexins and pannexins are expressed throughout
the cardiovascular system. The expression levels within the
vascular tree are dependent upon vessel type, localization
within the vessel, and the species being examined.
The expression differences between macrovessels vs.
microvessels and arteries vs. veins are continuing to
be examined; however, the specificity of antibodies
and detection of low expression levels remain limiting
steps to overcome. The majority of the data of pannexin
and connexin isoforms and their unique localizations
along the vascular tree comes from studies using rodent
models or human primary cells. Thus, species-dependent
differences also add another level of complexity to
our understanding of the localization and function of
these isoforms within the vascular wall. Below is a
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the expression of connexins and pannexins within the
vascular wall (Table 1).
Connexin expression in the vascular wall
Cx43 is, by far, the most studied connexin. It has been
well characterized and found to be expressed in the
vascular SMCs of large conduit vessels, such as the
aorta, in numerous species [28, 29]. The SMCs from
mouse and human resistance arteries and veins can also
express Cx43 [30–33]. Isolated primary human SMCs
and ECs from arteries and veins express Cx43 [33–35].
In vivo, Cx43 is expressed in arterial ECs of larger arteries
only in areas of non-laminar flow, such as branching
points, as well as in arterioles and capillaries, such as in
the brain [29–31, 36, 37]. In the murine vasculature, Cx43Table 1 Expression pattern of connexin and pannexin isoforms in v
muscle cells. ‘no’ indicates that a protein has yet to be identified in
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few studies have found expression in murine umbilical
cord vein, portal vein, and in human umbilical vein ECs
(HUVECs) [33, 36, 39, 40]. Cx37 expression in SMCs
has been demonstrated in arteries of various diameters
from various organs as well as in isolated primary
human SMCs [30, 31, 33, 36, 37]. It was specifically
noted that Cx37 is not found in veins from the coronary
or splenic circulations, although weak expression was
found in veins from other sections of the vascular tree
[36, 38, 39]. However, Cx37 is strongly expressed in ECs
that compose the valves in valved veins such as the
saphenous vein, but similar to Cx43, it is not expressed
in the surrounding non-valvular ECs of valved veins
[38]. Cx40 and Cx37 are both expressed in ECs of mice
and rats throughout the arterial tree as well as in isolated
human ECs [28, 30–34, 36, 37, 40].
Less information is available about the roles and
localization of Cx32, Cx45 and Cx47. A weak signal for
Cx45 has been observed in ECs from the bovine aorta
[41], but Cx45 expression is predominantly in SMCs as
well as in cultured HUVSMCs [28, 33, 37, 42]. Although
expression of Cx32 in vivo has only been reported in ECs
of large murine veins, the analysis of primary cultures of
human ECs suggest that Cx32 has significantly higher
expression in ECs from larger vessels, such as HUVECs
and HAECs, as compared to ECs from microvessels, such
as cultured human microvascular ECs (HMVECs) [43].
Cx47 has recently been found within a small subset
of ECs that compose the valves in veins [38]. As the
information about these connexins (Cx32, Cx45 and
Cx47) is just emerging, further studies are necessary to
determine their expression and functional roles within
the vasculature.
Pannexin expression in the vascular wall
Pannexin channels are expressed throughout the body.
The expression of these channels continues to be
explored, but recent data indicate that Panx1 is almost
ubiquitously expressed in murine ECs within arteries,
arterioles, and venules, as well as in isolated human
cells including an immortalized brain EC line, human
saphenous vein ECs (HSaVECs), and HUVECs [35, 44, 45].
Panx1 expression in murine SMCs occurs only in arterioles
and venules, while Panx3 is only found in arterioles
<100 μm in diameter [44, 45]. Panx2 has been observed in
SMCs of the pulmonary artery of mice and in the SMCs of
the rat middle cerebral artery (MCA) [44, 46]. Although
mRNA of all three pannexin isoforms were found in the
rat MCA, only Panx1 and Panx2 proteins were found in
ECs of these vessels [46]. Lastly, as with any membrane
bound protein that is expressed endogenously in low levels,
it is rather difficult to detect Pannexin mRNA from
small vessels. False-negative detection is a rather commonoccurrence and thus can not be taken to mean a lack of
expression. For this reason, protein detection in small
vessels in particular, is the most definitive way to detect
Pannexin 1; this in conjunction with a knockout animal to
validate expression. Overall, mouse and human expression
appear to be the most consistent and reliable expression
patterns, and thus physiologically relevant set of models,
whereas the rat appears to be more random in expression.
Regulation of connexin and pannexin function in the
vascular wall
Regulation of connexin hemichannels and pannexin
channels can occur via changes in extracellular and
intracellular Ca2+, pH or cell membrane voltage or via
post-translational modifications (PTMs). PTMs are
covalent protein modifications that alter protein function
via the addition or removal of chemical functional groups
to amino acid residues on the protein. A diverse array of
PTMs exists, including phosphorylation, S-nitrosylation,
glycosylation and ubiquitination, among others. These
PTMs have individual effects on protein function but can
also act in concert with other PTMs to regulate complex
physiological responses [35]. Protein modifications by phos-
phorylation and S-nitrosylation are central regulators of
vascular function due to the large influence of nitric oxide
synthase and kinase-mediated signaling pathways during
vasomotor responses in both arteries and veins [47, 48].
Research on connexin hemichannels and pannexin chan-
nels reveals evidence that the activity of these channels
can be regulated by phosphorylation. Understanding how
phosphorylation and S-nitrosylation modulates channel
function is critical for understanding how connexin hemi-
channels and pannexin channels contribute to vascular
homeostasis [49, 50].
Phosphorylation of connexin hemichannels
In the blood vessel wall, connexin hemichannels and gap
junction channels assist in coordinating vasoconstrictor
and vasodilator signaling between smooth muscle and
endothelial cells [51]. Overall, a large body of research
has been focused on the regulation of connexin gap
junctions by phosphorylation, but far less information is
available on the expression and functional control of
connexin hemichannels in the vasculature [52]. Recently,
a number of reports have observed that phosphorylation
events on connexin hemichannels can alter channel
permeability in cell culture [53]. However, there is
limited information about the functional regulation of
connexin hemichannels in vascular cells. Connexin
hemichannels have been identified on ECs and SMCs
[54–56]. In these cell types, connexin hemichannel
activation is linked to the release of ATP, a key sig-
naling molecule in the blood vessel wall [9]. Although
the mechanistic gating of connexin hemichannels by
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other cell types has suggested that hemichannels can be
directly regulated by kinases. Cx43 is a well-established
phospho-substrate for mitogen-activated protein (MAP)
kinases, as well as protein kinase C (PKC), which
have been extensively reviewed elsewhere [52, 57–59].
Additionally, phosphorylation of Cx43 at amino acid serine
residue S368 has been shown to reduce hemichannel
opening, decrease permeability, and change ion selectivity
[60, 61]. This inhibitory effect was in part confirmed in
the vascular endothelium, whereby hypoxia caused a
reduction in ATP release, depletion of surface Cx43, and
increased phosphorylation of Cx43 S368 [54]. It is
interesting to note that the inhibitory effects of hypoxia
on Cx43 hemichannels from cultured astrocytes have been
linked to the dephosphorylation of Cx43 hemichannels by
protein phosphatases, which suggests the existence of
a complex PTM network in the regulation of Cx43
hemichannels by phosphorylation [52]. Nevertheless,
future studies are needed to better understand how
phosphorylation of connexin hemichannels modulates
vascular function, especially in vivo.
Phosphorylation of pannexin channels
In addition to the presence of connexins in the vascular
wall, pannexin channels have emerged as the most
dominant regulator of extracellular purinergic signaling
in vascular function [62–64]. A number of serine,
threonine (T) and tyrosine (Y) phosphorylation sites have
been predicted for pannexins based on their amino
acid sequences, as well as putative recognition sites
for protein kinase C (PKC), protein kinase A (PKA),
and Ca2+/calmodulin-dependent protein kinase (CamKII)
(Fig. 1) [65–67]. However, there is still a lack of direct bio-
chemical evidence to link specific amino acid/kinase pairs
with channel function. The current landscape of Panx1
PTM by phosphorylation is dominated by the regulatory
role of tyrosine phosphorylation, which plays a unique
and crucial role in regulating vascular function [68–70].
Mechanistically, a link between pannexin channel
gating and tyrosine kinase phosphorylation was estab-
lished using Panx1-expressing J778 macrophages and
targeting the C-terminal Y308 amino acid of Panx1 in
rodent hippocampal brain slices [71, 72]. In the vasculature,
Lohman et al. recently confirmed the role for Src family
kinase (SFK)-dependent tyrosine phosphorylation at residue
Y198 of Panx1 in response to TNFα-receptor stimulation
in the venous endothelium [45]. In this study, stimulation
of ECs with TNFα resulted in an SFK-dependent increase
in phosphorylation of Panx1 at Y198, which was paralleled
by an increase in SFK activity [45].
Moreover, the Panx1 Y198 site was suggested to regulate
SMC contraction and vascular tone in resistance arteries
[62]. Based on earlier work that characterized a novelinteraction between the α1-adrenergic receptor and Panx1-
mediated ATP release, Billaud et al. demonstrated
that pharmacological and genetic inhibition of the
Panx1 intracellular loop motif containing Y198 prevents
the Panx1 channel activation, ATP release, and vaso-
constriction initiated by α1-adrenoceptor stimulation
[62, 63]. In addition, this study showed that SMC-specific
Panx1 deletion in mice, which exhibit blunted phenyleph-
rine (PE)-stimulated vasoconstrictor responses, could be
rescued by transfecting wild type Panx1 plasmids directly
into arterial SMCs, but not by plasmids containing a
mutated Y198 motif. These investigations suggest that
Panx1 tyrosine phosphorylation within both ECs and
SMCs could play a role in the regulation of vascular
function [45, 62]. However, this has yet to be proven
definitely and likely is a part of a much larger PTM
set of events that have yet to be uncovered.
Outside of tyrosine phosphorylation, little is known
about regulation of pannexin by serine/threonine PTM. In
one study using pan-phosphoserine/threonine antibodies,
the electrical stimulation of skeletal muscle was shown to
enhance serine/threonine phosphorylation of Panx1 [73].
The increase in phosphorylation was associated with
ATP release and dye uptake, which was sensitive to
channel blocking agents. In a second study, the Panx1
residue S206 has been put forth as a putative serine
phosphorylation site by protein kinase G (PKG) [74].
The inhibitory effect of the nitric oxide donor sodium
nitroprusside (SNP) on Panx1 channel currents was
shown to act through a cGMP-PKG dependent mechanism,
and mutation of the serine at residue 206 to alanine
blunted the SNP-dependent inhibition of Panx1 channel
currents [74]. However, this investigation did not directly
demonstrate substrate specificity of PKG for S206. In
the future, it will be important to determine if S206
phosphorylation by PKG negatively affects Panx1 channel
activity as Panx1-mediated ATP release has been shown
to control α1-adrenoceptor-induced vasoconstriction and
PKG signaling pathways are known to cause cessation of
vascular SMC contraction [62, 75].
S-Nitrosylation of connexin hemichannels
The addition of nitrosyl groups to cysteine (C) residues
(S-nitrosylation) is another important PTM in both
physiological conditions and disease [76, 77]. For connexins,
there is clear evidence that NO can influence gap junction
function in the vasculature, in both ECs and SMCs [78–81].
However, limited evidence exists for the regulated gating
of connexin hemichannels by S-nitrosylation in the blood
vessel wall. The mechanisms by which NO regulates
connexin hemichannel activity have primarily been inves-
tigated in the central nervous system, mainly in astrocytes
[53, 82]. However, it is important to note that both
astrocytes and endothelial cells express the enzyme NO
Fig. 1 Diagram of mouse Pannexin 1 membrane topology and post-translational modifications. Based on sequence analysis using the UniProt
database, Pannexin 1 is predicted to contain four transmembrane regions. It contains four conserved extracellular cysteine residues (blue) in the
extracellular loops and a confirmed N-glycosylation site (green) necessary for plasma membrane translocation. Multiple post-translational modification
sites by S-Nitrosylation (pink), phosphorylation (yellow), or proteolytic caspase cleavage (gray) have been confirmed to regulate channel
gating. Additional post-translational modifications were predicted and annotated using PhosphoSitePlus (orange)
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PTM mechanisms that regulate connexin hemichannel
activity in these two cell types.
A number of studies have linked the regulation of
connexin hemichannels with the production of NO.
S-Nitrosylation has been proposed to regulate Cx43
hemichannels in astrocytes and cardiomyocytes, whereby
conditions of oxygen deprivation and metabolic inhibitioncan enhance hemichannel activity as determined by
pharmacology and in vitro [83, 84]. The potential modula-
tion of connexin hemichannels by NO-mediated events
has been linked to the functional regulation of vasodilator
responses. Using connexin-deficient HeLa cells, Figueroa
et al. demonstrated that Cx43, Cx40, and Cx37 could be
stimulated to open when treated with NO donors and
additionally could act as a conduit for NO transmission
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(ACh)-induced vasodilation and the diffusion of NO
from ECs to SMCs could be blocked in mesenteric
arteries by inhibiting connexin-based channels. However,
future studies are needed to determine the extent to which
NO-activated connexin hemichannels contribute to the
regulation of vascular function.
S-Nitrosylation of pannexin channels
In addition to connexin hemichannels, evidence indicates
that Panx1 channels can be regulated by S-nitrosylation. It
was previously demonstrated that Panx1 channels can be
activated by ischemic conditions in neurons, and that
inhibition of the neuronal isoform of NOS (nNOS) during
oxygen/glucose deprivation (OGD) blocks Panx1 channel
activity in a NO-dependent and redox-sensitive manner
[85, 86]. Direct evidence for a potential PTM site at Panx1
residue C28 was later identified in zebrafish using targeted
mutagenesis experiments on cysteine residues in the
intracellular and transmembrane domains of Panx1 [87].
Two later studies revealed additional residues (C40 and
C346) as potential PTM sites of Panx1 [88]. Mutations of
these two individual residues to serines resulted in a
constitutively active channel [88]. Moreover, substitution
of any of the four extracellular cysteine residues in Panx1
(C66, C84, C245, and C264) resulted in complete loss of
channel function [89].
Although the previous studies did not identify Panx1
PTM by S-nitrosylation in a physiological context, they
did set the stage for an investigation by Lohman et al,
which demonstrated that multisite S-nitrosylation may
be important for Panx1 channel gating in the vasculature
[90]. The treatment of HEK and HAECs with the
NO donor S-nitrosoglutathione (GSNO) induced Panx1
S-nitrosylation; however, instead of activating Panx1 as
observed in neurons, NO had an inhibitory effect on
channel currents and ATP release. This inhibition could
be reversed by the reducing agent DTT. Furthermore,
dual mutation of both C40 and C346 residues to alanine,
but not either point mutation alone, was necessary to
prevent GSNO-stimulated inhibition of Panx1 channel
currents and ATP release. The results of this study
highlight a potential negative regulatory mechanism
of Panx1 channel gating by S-nitrosylation, which
may balance vasoconstrictor responses produced by
Panx1-mediated ATP release in SMCs of resistance
arteries [62]. More recently, a similar investigation
looking at the effects of NO donors on Panx1 activity in
human embryonic kidney 293 (HEK) cells confirmed the
observation of Lohman et al that NO donors closed Panx1
channels [74]. However, in this investigation, a PKG-
dependent phosphorylation mechanism was suggested to
participate in the control of channel activity, particularly
by the stimulation of soluble guanylyl cyclase via NO. Themechanistic discrepancy between the two studies may be
due to complex PTM regulatory signals, where multiple
signaling cascades are involved in regulating pannexin
channel gating as it relates to vascular function.
Connexin hemichannels and pannexin channels in the
control of vasomotor tone
The regulation of blood flow distribution in the tissues
relies on the well-integrated control of the microvascular
resistance to blood flow by the adjustment of the
diameter of resistance vessels, which depends on the
level of constriction of SMCs (i.e. vasomotor tone). The
contractile state of SMCs depends on the cytoplasmic Ca2+
concentration and Ca2+ sensitivity of the contractile
machinery. Thereby, smooth muscle membrane potential
plays a pivotal role in the regulation of vasomotor tone by
temporally controlling the open probability of L-type,
voltage-dependent Ca2+ channels [91, 92]. However, it
is important to note that vasomotor tone is finally
determined by the balance between a smooth muscle-
dependent constrictor tone and an endothelium-dependent
vasodilator tone [93, 94].
Connexins and pannexins in smooth muscle cell function
The SMC-constrictor tone is mainly determined by the
development of myogenic tone and the activity of the
sympathetic system (i.e. sympathetic tone) [95, 96].
Myogenic tone is an intrinsic property of vascular
smooth muscle and corresponds to the ability of vessels to
develop a basal tone in response to the intravascular blood
pressure [96, 97]. Interestingly, development of myogenic
tone was found to be sensitive to blockers of connexin-
based gap junctions in resistance arteries [98–100]. In
small mesenteric resistance arteries, the myogenic
response was blocked by 18α-glycyrrhetinic acid
(18α-GA) and the connexin mimetic peptide 37, 43Gap27,
which blocks channels formed by Cx37 or Cx43 [98].
Interestingly, the inhibition of the myogenic vasoconstric-
tion was associated with a reduction in the pressure-
induced SMC depolarization and the subsequent Ca2+
influx, which suggested that the inhibition was not related
to synchronization of Ca2+ signaling, but rather to
earlier signaling events such as the initiation of SMC-
depolarization [98]. It is important to note that the effect
of connexin mimetic peptides such as 37, 43Gap27 on
connexin channels is time dependent. It has been
suggested that application of these peptides for short
periods of time (from 10 to 45 min) only inhibits
hemichannel activity, without affecting gap junction
communication, which are blocked only by much longer
(>1 hr) periods of treatment [34, 101–103]. The myogenic
response was evaluated only after 1 hr of treatment
with 37, 43Gap27, thus the contribution of gap junc-
tion channels and hemichannels must be further
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and, therefore, may directly form part of the vascular
smooth muscle pressure-sensitive mechanism involved in
the development of myogenic vasoconstriction [104]. As
Cx37, but not 43, was detected by immunofluorescence in
SMCs of these mesenteric arteries, the activation of Cx37
channels was proposed to be involved in the pressure-
induced smooth muscle cell depolarization that triggers
the initiation of the myogenic response [98]. However, the
resting basal vasomotor tone of cremaster muscle
arterioles of Cx37 knockout (KO) mice was not different
to that observed in wild type animals, thus the participa-
tion of other Cxs, like Cx43 and/or pannexins cannot be
definitively ruled out [15].
In addition to the myogenic tone, connexin hemichan-
nels may also involved in the sympathetic nerve-triggered
vasoconstriction. The sympathetic vasomotor tone is
primarily mediated by norepinephrine-evoked activation of
α1-adrenoceptors in SMCs [95]. It was recently re-
ported that blockade of connexin-based channels with
18β-glycyrrhetinic acid (18β-GA) or the Cx40 blocking
peptide 40Gap27 attenuates the increase in perfusion
pressure induced by PE in isolated, perfused rat kidney, an
effect observed within a few minutes of peptide applica-
tion [105]. Furthermore, the vasoconstrictor response was
not altered by the connexin-blocking peptides 37, 43Gap27
or 43Gap26, a Cx43-specific channel blocker, suggesting
participation of Cx40 hemichannels in the response [105].
The inhibition of the vasoconstriction observed in the
presence of 40Gap27 suggests the participation of Cx40
hemichannels in the α1-adrenoceptor-mediated control of
vasomotor tone; however, the mechanism involved has
not been elucidated. This also highlights the serious
problem of pharmacological reliance for determination
of connexin hemichannel function. This therefor requires
active investigation and the impetus is certainly on the
connexin hemichannel field to definitely prove these
exist in vivo and without the need to use vague inhibitors
(e.g., as discussed by [106]).
The vasoconstrictor response initiated by α1-adrenoceptor
activation in arterioles appears to be very complex and also
involves autocrine signaling mediated by ATP release
through pannexin channels. Recently Billaud et al. showed
that stimulation of α1-adrenoceptors leads to Panx1 channel
opening, which provides the pathway for ATP release
[63]. The ATP released via Panx1 channels contributes, in
great part, to the α1-adrenoceptor-mediated vasoconstric-
tion through the activation of P2Y receptors [62, 63, 107].
Interestingly, this complementary vasoconstrictor mech-
anism is only coupled to α1-adrenoceptor activation
while the response to serotonin or endothelin-1 is not
affected by typical Panx1 channel blockers such as
the Panx1 mimetic peptide 10Panx and probenecid,
which was confirmed in the SMC Panx1-deficientmice [62]. This observation has now been confirmed
independently pharmacologically [108] and genetically
[109] in mouse mesenteric arterioles (as well as humans
[data not shown]) highlighting the importance of the
Panx1-α1-adrenerigc interaction, especially for transla-
tional outcomes.. The activation of Panx1 channels was
found to rely on the specific amino acid sequence YLK,
corresponding to residues 198 to 200 of the intracel-
lular loop of Panx1 [45, 62, 63]. This suggests that phos-
phorylation at Tyr198 may mediate the α1-adrenoceptor-
induced Panx1 channel opening, as recently reported by
Lohman et al. to occur in the activation of Panx1 channels
in venous ECs in response to TNFα [45, 62, 63].
Connexins and pannexins in endothelial cell function
ECs play a central role in the regulation of vasomotor
tone primarily by the production of Ca2+-dependent
vasodilator signals such as NO, prostaglandins and EDH
[4, 11, 12, 110]. Interestingly, NO and prostaglandins have
been shown to be released through connexin hemichannels
[78, 111]. It is important to note that NO may also induce
the opening of hemichannels formed by the vascular
connexins Cx37, Cx40 and Cx43, probably through
S-nitrosylation, as demonstrated in the case of Cx43
hemichannels [78, 84]. In addition, several reports show
that ECs may release ATP, a potent endothelium-dependent
vasodilator, through Cx43 hemichannels and Panx1
channels [45, 54, 90, 112–117]. Therefore, endothelial ATP
release may be involved in the control of vasomotor tone.
Consistent with this hypothesis, endothelial Panx1-
dependent ATP release was recently proposed to facilitate
or enhance the EDH signal activated by ACh in ECs from
mouse saphenous artery through a mechanism similar to
that described for the response to PE in SMCs [118]. In this
case; however, the increase of extracellular ATP concentra-
tion not only triggered the activation of P2 receptors
directly by ATP, but also P1 receptors indirectly by the
hydrolysis of ATP to adenosine, which was proposed to
contribute to the ACh-induced increase in EC [Ca2+]i [118].
Paradoxically, global deletion of Panx1 resulted in a
selective reduction of the SKCa and IKCa-initiated EDH-
mediated vasodilation, without affecting the NO-dependent
vasodilator component of the response to ACh, although
both signals (EDH and NO) are Ca2+-dependent [118].
Ablation of Panx1 in these animals did not evoke a compen-
satory change in the expression of Panx2 or Panx3 in the
saphenous artery; thus, the mechanism by which Panx1-
driven ATP release activates selectively SKCa and IKCa in
ECs will have to be addressed in further investigations [118].
Connexins and pannexins in the vessel wall inflammatory
response
The role of connexin-based intercellular gap junction chan-
nels in inflammation has been investigated for decades.
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gap junctions play an important role regulating cell-to-cell
communication during inflammation-related diseases such
as atherosclerosis, hypertension or diabetes (for reviews see
[4, 119, 120]). However, longstanding evidence also indi-
cates that functional connexin hemichannels are involved
in inflammation. While most research of connexin hemi-
channels in inflammation has been focused on the brain, by
investigating astrocytes, neurons, and microglia (for reviews
see [121, 122]), there is in vitro evidence for both pro- and
anti-inflammatory roles for connexin hemichannels in the
vasculature (Table 2). Pannexin channels that are highly
expressed throughout the immune and cardiovascular
system [45, 123, 124] are known to be key players during
inflammation, but less is known about the mechanism by
which pannexins participate in the cellular inflammatory
response [125]. A role has been shown for pannexins in
ischaemic conditions, pro-inflammatory neurotransmitter
signaling, and surgically induced injuries on ECs that are
presented below (Table 2).
Role of connexin hemichannels and pannexin channels
under inflammatory conditions
To date, there are only few studies carving out the distinct
regulation between the activation of connexin hemichannelTable 2 Pathophysiological conditions linked to connexin hemichan
MS: mesangial cells; n.d.: not determined
Protein Condition
Connexin hemichannelsa




Cx43 Acute ischemic stroke mimicking (absence of extracellular Ca2+)
Cx43 Retinal ischemia-reperfusion injury
Cx43 Retinal ischemia-reperfusion injury
Cx43 Bradykinin-induced inflammation
Cx43 Thrombin-induced inflammatory response
Cx43 Diabetes (high glucose/cytokines treatment)-mimicking conditions
Cx43 Surgical implantation of medical devices
Pannexin channelsa
Panx1 Acute ischemic stroke mimicking (absence of extracellular Ca2+)
Panx1 Cerebral ischemia-reperfusion injury
Panx1 Pro-inflammatory neurotransmitter CGRP release
Panx1 M-CSF-induced HSP-70 release immune response
Panx1 TNFα-induced acute inflammation
Panx1 Thrombin-induced inflammation
Panx1 Surgical harvesting of vessel
aNote that the connexin hemichannel work has been proposed almost exclusively t
genetic and pharmacological confirmationand/or pannexin channels. Kaneko et al. for example
showed a role for both connexin hemichannels and
pannexin channels in a blood–brain barrier (BBB) model
system [35]. Using the human cerebral microvascular
endothelial cell line hCMEC/D3, conditions mimicking
acute ischemic stroke led to the opening of both Cx43
hemichannels and Panx1 channels, as observed by
increased dye uptake and calcein efflux, respectively.
Pharmacological inhibition with CBX or 18α-GA and
knockdown with either Cx43 siRNA or Panx1 siRNA
prevented the dye uptake and calcein efflux [35]. In
another study, regulation of BBB ECs under inflammatory
conditions was linked to connexin hemichannel opening;
specifically bradykinin, a pro-inflammatory agent, evoked
an increase in BBB permeability in rats through the
activation of intracellular Ca2+ oscillations in ECs by a
pathway sensitive to the Cx43 inhibitor Gap27, indicating
the involvement of hemichannel opening and purinergic
signaling in response to bradykinin [34].
Ischemic injuries resulting in inflammation also induce
the opening of connexin hemichannels. In retinal ischemia-
reperfusion (I/R) injury in rat, the opening of Cx43
hemichannels and gap junctional communication was
shown to play a role in inflammation, vascular permeability
and neuronal death [126]. In a similar study, I/R led tonel or pannexin channel regulation. EC: endothelial cells;
Regulation Cell type Tissue origin Species Reference
Opening EC Brain Mouse [128]
Opening EC Brain Rat [124]
Closure EC Skin Human [54]
Opening EC Brain Human [35]
Opening EC Retina Rat [123]
Opening EC Retina Rat [124]
Opening EC Brain Rat/bovine [34]
Closure EC Cornea Bovine [129]
Opening MS Kidney Mouse [132]
Opening EC n.d. Human/rat [130]
Opening EC Brain Human [35]
Opening n.d. Brain Rat [125]
Opening EC Mesentery Rat [37]
Opening EC n.d. Human [126]
Opening EC Diverse Mouse/human [45]
Opening EC Umbilical vein Human [112]
Opening EC Saphenous Vein Human [131]
hrough pharmacological extrapolation, whereas the pannexin work combines
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retina, increased Cx43 expression, co-localization of
activated astrocytes with ECs, and glial fibrillary acidic
protein (GFAP) de-organization close to blood vessels
resulting in retinal ganglion cell death [127]. These
effects were prevented by treatment with Cx43 mimetic
peptide during reperfusion, which strongly supports a
Cx43 hemichannel-dependent mechanism during I/R
injury [127]. Cerebral I/R injury in rats induced
activation of astrocytes, microglia and further subsequent
inflammatory responses. Treatment of the animals before
or even after the induced ischemia with different
doses of probenecid, a pannexin inhibitor, prevented
I/R injury-induced inflammation and cell death by
preventing increased expression of cathepsin B and
calpain-1 and by increasing heat shock protein 70
(HSP70) release [128, 129]. Although these studies
were done in different organs, namely retina and
brain, they suggest a role of connexin hemichannels
and pannexin channels in the I/R injury.
Hypoxia alone also appears to independently regulate
connexin-based hemichannel opening in vitro. In rat brain
microvascular endothelial R840K-05a cells, hypoxia-
induced cell death could be rescued by the application of
hemichannel inhibitors carbenoxolone (CBX), La3+ or
Cx43 mimetic peptide [127]. Interestingly, astrocytes at
penetrating vessels in the medulla oblongata release ATP
via Cx26 hemichannel under hypercapnia (elevated arterial
PCO2) to signal for breathing regulation [130]. Both condi-
tions, low O2 levels and increased CO2 levels, signal via
connexin hemichannel-mediated ATP release. However,
studies also showed that in human microvascular ECs of
dermal origin, induction of hypoxia for 48 h attenuated
Cx43 hemichannel-mediated ATP release. In this study,
Cx43 transcript, total, and surface protein levels were all
reduced, and Cx43 showed higher phosphorylation at S368
(which leads to a closed state of this hemichannel) [54].
The regulation of Cx43 hemichannel activity as well as a
potential role of pannexin channels in hypoxic conditions,
remains to be investigated.
Exposure to pathogen-associated molecular patterns
(PAMPs) causes the opening of Cx43 hemichannels in
ECs of the BBB, which induces an early inflammatory
process. Incubation of b.End5 cells, a murine brain
endothelial cell line, with the gram-positive cell wall
component peptidoglycan for 24 h induces an ATP release
via PKC-dependent Cx43 hemichannel opening, resulting
in increases in mRNA expression levels of Cx43,
Interleukin-6 (IL-6) and Toll-like receptor 2 (TLR2). These
results demonstrate the role of Cx43 hemichannels in early
inflammatory response, which occurs before changing the
inflammatory related gene expression [131]. Another pro-
inflammatory TNFa-induced ATP release was shown to be
Panx1-dependent. Lohman et al. recently identified animportant mechanism of regulation of endothelial Panx1
channels in TNFα-induced inflammation ex vivo, using
dissected mesenteric veins, and in vitro, using isolated
human primary venous ECs [45]. Application of TNFα
induced, within minutes, ATP release into the lumen of
cannulated veins or into the media of cultured cells.
Importantly, this effect was only seen in veins or venous
ECs, but not in arteries or arterial ECs. This ATP release
was Panx1 channel-mediated as shown by prevention of
ATP release with pharmacological inhibitors, such as CBX
or 10Panx, and with siRNA-mediated knockdown of Panx1.
siRNA knockdown of Cx43, conversely, had no effect.
Furthermore, cannulated veins from EC-specific Panx1-
deficient mice failed to release ATP following TNFα stimu-
lation. TNFα induced SFK-dependent phosphorylation at
tyrosine Y198 in the intracellular loop of Panx1, leading
to the opening of the channel. Intravital microscopy
demonstrated that TNFα induced leukocyte adhesion and
emigration was blunted in EC-specific Panx1-deficient
mice [45]. In a similar study, thrombin induced a robust,
Ca2+-dependent ATP release via Panx1 channels in
HUVECs [115]. Pro-inflammatory mediators like thrombin
or histamine were also reported to induce the inhibition of
Cx43 hemichannel-mediated ATP release by either a rapid
and transient RhoA activation or the activation of
phospholipase C (PLC), depending on which G protein
was expressed in the cell [132]. These results highlight
Panx1 as well as Cx hemichannels as a key protein for the
crosstalk between cytokine and purinergic signaling in
early inflammation.
In addition to known vascular diseases, surgical im-
plantation of medical devices can also trigger inflam-
matory responses that involve connexin hemichannel
activity. This inflammatory response leads to thickening of
the implant/muscle interface and increased numbers of
infiltrating neutrophils [133]. Application of a Cx43
mimetic peptide (JM2), which binds to the microtubule
binding domain of Cx43, resulted in the inhibition of
Cx43 hemichannel-mediated ATP release in cultured
HMVEC [133]. When applied to rats with a silicone
implant, the JM2 peptide restored the matrix formation
and cellularity surrounding the implants and reduced the
number of infiltrated neutrophils, suggesting that blockade
of Cx43 hemichannel opening and subsequent ATP release
into the vasculature could reduce inflammation and
improve tissue healing after implant surgery [133]. Similar
to Cx43 hemichannel regulation during surgical interven-
tion, surgical harvesting of human saphenous veins
induced endothelial and/or smooth muscle injuries
resulting in cellular dysfunction and intimal thickening,
possibly due to ischemia in the vein following extraction.
Intimal injuries during surgery led to ATP release, which
evoked P2X7 receptor and/or Panx1 channel activation
with subsequent P2X7 receptor downstream signaling.
Table 3 Expression pattern of connexin and pannexin isoforms
in red blood cells (RBCs) and platelets. ‘no’ indicates that a
protein has yet to be identified in those cells
Protein RBCs Platelets References
Cx32 no low levels [147]
Cx37 no yes [146, 147]
Cx40 no yes [147]
Cx43 no low levels [147]
Panx1 yes yes [139, 140] / [149, 150]
Panx2 no no
Panx3 no no
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probenecid and oxidized ATP, respectively, prevented
inflammatory intimal hyperplasia and, therefore, could
be a possible therapeutic target for improving successful
grafting of vessels [134].
A functional role of Panx1 was also suggested in the
signaling between the nervous and vascular system
under pro-inflammatory conditions. Stimulation of primary
arterial endothelial mesenteric cells and intact mesenteric
arteries with the neurotransmitter calcitonin gene-related
peptide (CGRP) leads to Panx1 channel opening as shown
by ethidium uptake, which was prevented by the spe-
cific inhibition of CGRP receptors with the peptide
CGRP8-37 or the blockade of Panx1 channels with
probenecid. Furthermore, stimulation of perivascular
sensory nerves with capsaicin led to CGRP release and
downregulation of endothelial NOS (eNOS) expression,
linking pro-inflammatory induced neurotransmitter
release to the development of endothelial dysfunction
during inflammation via decreased eNOS protein
levels [37]. A possible role for connexin hemichannels
was not investigated.
The development of renal and cellular alterations
during diabetes in rats has been linked to increased
Cx43 hemichannel opening in mesangial cells, specialized
cells surrounding blood vessels in the kidney. Mouse
MES-13 mesangial cells treated with high glucose and
cytokines (tumor necrosis factor α (TNFα), IL-1β) for 48 h
displayed an increase in cellular permeability that
correlated with an enhanced uptake of ethidium bromide,
suggesting an increase in connexin hemichannel opening
[135]. However, pannexin channels cannot be ruled out
and necessitate further pharmacological or genetic experi-
ments. Taken together the data predominately suggest that
preventing/reducing connexin hemichannel or pannexin
channel opening may reduce inflammation in response to
various stimuli.
Connexins and pannexins in anuclear circulating blood cells
Pannexins in RBCs Long viewed simply as carriers of
oxygen, in the past two decades red blood cells (RBCs)
have received renewed attention for their potential
‘erythrocrine’ function; i.e., the ability to influence their
own distribution across the vasculature by participating
in signaling pathways that result in the modulation of
vascular tone, thus controlling blood flow to tissues with
relatively greater or lesser need of oxygenation [7, 136, 137].
Ellsworth et al. proposed in 1995 a pathway involving RBC
release of ATP into the vessel lumen based on the
knowledge that RBCs release ATP in response to hypoxic
conditions and that ATP application results in significant
increases in RBC supply rate to both arterioles and venules
at the end of a capillary network [136, 138]. ATP released
by RBCs is thought to bind to G protein-coupled P2Yreceptors on the endothelium, initiating a signaling
cascade to produce and release peripheral vasodilatory
signaling molecules such as NO and prostacyclin
[136]. Upstream transmission of this vasodilator response
allows blood flow to be modulated to match local oxygen
demand [139]. ATP is released when human RBCs are
exposed to O2 tensions equivalent to 50% hemoglobin
oxygen saturation [140]. Further supporting the central
role of RBCs in this process, perfusion of blood vessels
with RBCs was shown to be necessary to elicit vessel
dilation in response to hypoxia [141]. This phenomenon is
also supported by exercise data showing that changes in
the levels of circulating ATP in blood plasma are propor-
tional to changes in the oxygenation state of hemoglobin
in RBCs [137].
A mechanism for ATP release was provided by the
detection of functional Panx1 channels in RBCs, and by
the lack of Cx43 and vesicular release of ATP in RBCs
under physiological conditions (Table 3) [142, 143].
Inhibition of RBC ATP release with the pannexin inhibitors
CBX, probenecid, and 10Panx later clarified that Panx1 is
responsible for ATP release from human RBCs in response
to hypoxia, though not for a separate mechanism of ATP
release in response to activation of the prostacyclin receptor
[144]. Additionally, mechanical deformation of RBCs has
been found to induce ATP release via a pathway similar to
that of hypoxia-induced ATP release, with impairment of
RBC deformability also impairing hypoxic ATP release
[140, 145]. The exact mechanism of Panx1 opening in
response to hypoxia or RBC deformation remains unsolved,
but a variety of data suggests that Panx1 lies downstream of
the mechanosensitive G protein-coupled receptor Gi,
(e.g. P2Y receptors), adenylyl cyclase, and cAMP synthesis
[140, 144, 146]. However, RBCs are still able to release
ATP in response to direct Gi stimulation when RBC
deformation is prevented. These observations suggest that
hypoxia and deformation of RBCs is linked, possibly
by Gi to initiate the signaling cascade culminating in
Panx1-dependent release of ATP into the vessel lumen
[145]. The resulting NO that serves as a vasodilator may,
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[140]. While the mechanism has not been fully explained,
this negative feedback is thought to occur via NO-derived
inactivation of Gi [146]. However, the recent discovery that
Panx1 can be inhibited directly by NO via S-nitrosylation
on amino acid residues C40 and C346 offers an alternative
explanation that must be investigated [90].
Connexins and Pannexins in Platelets Platelets are
anuclear cells found in blood that, in the presence of
endothelial damage, bind exposed collagen on the basement
membrane of the vessel wall. Further, they are activated to
release α-granules that contain a variety of growth and
clotting factors and dense granules that contain ADP, ATP,
Ca2+, serotonin, and histamine; signals that promote further
platelet aggregation [147]. Certain pathologic condi-
tions result in elevated platelet activity outside of normal
hemostasis, including chronic infectious or inflammatory
conditions such as atherosclerosis [147]. When an
atherosclerotic plaque ruptures, platelets erroneously
become activated, often leading to thrombosis and
possible vessel occlusion [148]. Interrupting pathogenic
platelet activation and aggregation is therefore an
important strategy to prevent and combat thrombosis.
The most common connexin found on the surface of
human platelets by immunohistochemistry is Cx37, with
lower amounts of Cx32, Cx40, and Cx43 also reported
(Table 3) [149, 150]. Platelet α-granule and dense granule
secretion was significantly reduced after platelets were
stimulated with collagen-related peptide (CRP-XL) in
the presence of connexin inhibitors, 37,43Gap27, CBX
or 18β-GA, suggesting a role for connexin hemichannels
during platelet activation [150]. In addition, connexin
inhibitors decreased binding of individual platelets to
fibrinogen and inhibited platelet aggregation [150].
However, Cx37-deficient mouse platelets did not reveal a
significant difference in α-granule and dense granule
secretion compared to WT platelets when stimulated
with CRP-XL, implicating a connexin other than Cx37
mediates platelet granule secretion [150]. Overall, the
findings of Vaiyapuri et al. suggest that connexin
hemichannel activity plays an important role in plate-
let activation and initiation of aggregation via fibrino-
gen binding.
Interestingly, 40Gap27-treated human platelets and
Cx40-deficient mouse platelets both showed decreased
fibrinogen binding compared to WT when platelets were
stimulated with CRP-XL [151]. Inhibition or deletion of
Cx40 in platelets also showed significantly decreased
expression of P-selectin, a marker of α-granule secretion
[151]. These studies may support a role for Cx40
hemichannels, in promoting platelet activation and
aggregation. Further investigation of how Cx40 hemi-
channels may be activated is required.Panx1 has also been identified on the surface of human
platelets, but not Panx2 or Panx3 [152, 153]. Panx1
inhibition or deletion in platelets resulted in impaired
collagen-induced aggregation, ATP release, and Ca2+
influx [152, 153]. Molica et al. reported that, in platelets,
Panx1 co-immunoprecipitates with P2X1, an ATP-gated
channel involved in thrombosis [152]. Inhibition of P2X1
with NF449 decreased collagen-induced platelet aggrega-
tion, which was not restored by potassium-stimulated
opening of Panx1 channels [152]. Taylor et al. found that
the Panx1 inhibitors probenecid and CBX, impaired colla-
gen, thrombin, and TXA2 analogue-induced Ca
2+ influx,
possibly through P2X1 signaling [153, 154]. Together,
these data suggest that P2X1 signaling occurs downstream
of Panx1 [152–154]. Platelets from patients homozygous
for the Panx1-400C polymorphism, which results in a
change from glutamine to histamine at residue 5 in the
Panx1 amino-terminus, release elevated amounts of ATP
at rest when stimulated with K+ and demonstrate
increased collagen-induced platelet reactivity compared to
platelets with the Panx1-400A allele coding for glutamine
[152]. In addition, a higher frequency of the Panx1-400C
allele was found in cardiovascular patients with hyper-
reactive platelets compared to those with hypo-reactive
platelets [152]. Further evaluation of connexin- and
pannexin-dependent signaling in platelets may provide a
new therapeutic target for cardiovascular patients.
Conclusions
Connexin hemichannels and Panx channels may play an
important role in the vascular system, not only in the
coordination of endothelial and smooth muscle cell
signaling, but also in the control of blood cell function
in normal conditions as well as during inflammation.
Although several connexin and Panx isoforms are
expressed in the vessel wall and blood cells, the signaling
mediated by connexin hemichannels and Panx channels
in the vascular system seems to rely mainly on channels
formed by Cx43 and Panx1, respectively. Both Cx43 and
Panx1 have several sites that can be modulated by
phosphorylation and S-nitrosylation, which provides
mechanisms for rapid and fine regulation of the activity
of these channels and for cross talk between the interac-
tions of different signaling pathways.
The most relevant signaling mechanism mediated by
connexin hemichannels and Panx channels between the
cells of the vascular system is the release of ATP. However,
connexin hemichannels and Panx channels are also
permeable to Ca2+, which is a key second messenger
in the control of vasomotor tone by both endothelial
cells and smooth muscle cells. In any case, the possible
direct contribution of these channels to the regulation of
intracellular Ca2+ dynamics in the cells of the vessel wall
remains to be determined. In addition, although most cells
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channels, it should be noted that the function of these
channels is not redundant, as can be observed, for
instance, in the vasoconstriction of smooth muscle cells
initiated by intravascular blood pressure (i.e. myogenic
response) or α1-adrenoceptor activation. The functional
specificity of these channels suggests that the manipula-
tion of their activity may provide the opportunity to
design novel pharmacological strategies for the treatment
of diseases associated with the development of vascular
dysfunction or inflammation.
In summary, although multiple connexin and pannexin
isoforms have been found in the vasculature as well as the
anuclear circulating cells, their channel regulations and
functions remain a topic of intense investigation. The
separation between connexin hemichannel and pannexin
channel function is difficult to ascertain, however it
remains vital to explore these mechanisms as there
are both convergent and divergent functions throughout
the vasculature to maintain homeostasis.
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